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Abstract
To understand the causes of disease and improve diagnosis and treatment regimes,
biomedical researchers need access to large numbers of well-characterized data and
samples. Over the past decade, biobanks have been established across Europe to collect
and manage access to data and samples. The challenge that we face is how to develop the
tools and collaborations to enable researchers to access samples and data from a net-
work of biobanks, rather than applying to individual biobanks. One of the perceived
stumbling blocks to achieving this is represented by the different legal requirements in
each country. The aim of the BioSHaRE-European Union (EU) project is to address these
challenges by developing tools and methods for researchers to access and use pooled
data from different cohort and biobank studies. The purpose of this article is to identify
and compare the key legal requirements regarding research use of data across biobanks
based in Finland, Germany, the Netherlands, Norway and the UK. Our investigation
starts with the analysis of the key differences for the use of data between these coun-
tries. As a result, we identified three key areas where legal requirements differ across the
five BioSHaRE-EU jurisdictions, namely, in the definition of personal data, the require-
ments regarding pseudonymization and processing for medical research purposes. This
article provides an overview of these differences and describes them in the light of the
proposed EU regulation on data protection.
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Introduction
The role of biobanks
Biomedical research relies on the collection of personal information and human tissues
held in biobanks,1 in order to obtain the sample sizes needed to understand the aetiology
of a given disease. Research is increasingly international, and samples obtained from
many different biobanks, located in different jurisdictions, are now gathered to facilitate
the creation of mega data sets.2
1. On a legislative level, there is no uniform definition of a biobank. Furthermore, it is not clear
whether the term ‘biobank’ includes samples and related data. For the purpose of this article,
the term biobank is defined as ‘an organized collection of human biological material and
associated information stored for one or more research purposes’. Available at: http://
www.p3g.org/biobank-lexicon (accessed 8 April 2014).
2. G. Church, C. Heeney, N. Hawkins, J. de Vries, P. Boddington, J. Kaye, M. Bobrow and B.
Weir, ‘Public Access to Genome-wide Data: Five Views on Balancing Research with
Privacy and Protection’, PLoS Genet 5(10) (2009), p. 1; J. Gillot, ‘Human rights, privacy
and medical research: analysing UK Policy on tissue and data’, Genetic Interest Group
(2006). Available at: http://www.bionews.org.uk/page_37875.asp; G. Laurie, P. Mallia, D.
A. Frenkel, A. Krajewska, H. Moniz, S. Nordal, C. Pitz and J. Sandor, ‘Managing Access
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Biobanks are fundamental research tools for the advancement of biomedical research.
Their value is not limited to the stored samples and data, but goes beyond, and includes
all the information that can be obtained from the analysis of these samples, the possibility
to combine it with other relevant data, including clinical data, and the fact that they
enable long-term research projects providing access to those resources over time. This
is particularly true for large-scale longitudinal biobanks, which are generally used for
epidemiological research projects and population biobanks, which usually store sensitive
health data of thousands of individuals and may provide the basis for research in the field
of personalized medicine. Small collections of samples and data, in academic or hospital
settings, are also fundamental to contribute in the advancement of specific research proj-
ects, particularly when combined with results deriving from different studies. In general,
biobanks may differ under different aspects, such as size, research design and types of
biological samples collected, method of sample/data collection, processing, storage, and
the research focus. The same diversity can be found in the relevant regulatory frame-
work, but such jurisdictional differences may represent an obstacle for the pooling of
data across the different biobanks or cohorts.
A fragmented regulatory framework
The law that applies to biomedical research within Europe is complex. It brings in dif-
ferent heads of law, such as data protection, privacy and tissue regulation as well as med-
ical research regulations. At the core of this multifaceted legal framework is a distinction
between sample and data that are governed by different legal regimens.3 Whilst there is
not one European legal instrument that applies specifically to biobanks, there are specific
national biobanking legislations in some jurisdictions. One of the concerns is that
although researchers operate across borders, the regulatory framework for biobanks is
nationally based, and this may impede the pooling of data from biobanks.4
The laws relating to the processing of personal data in Europe share a common origin
in the Data Protection Directive 95/46/EC (in this article simply ‘the Directive’),5 but
there are some differences between member states regarding its implementation, partic-
ularly, in regard to biomedical research, which is most evident in the interpretation of
key principles. The purpose of this article is to identify and compare the key legal
requirements regarding research use of data in Finland, Germany, the Netherlands, Nor-
way and the UK. All these countries are part of the BioSHaRE-European Union (EU)
to Biobanks: How Can We Reconcile Individual Privacy and Public’, Medical Law
International 10 (2010), p. 315–337.
3. T. Schulte in den Ba¨umen et al., ‘Data Protection and Sample Management in Biobanking –
A Legal Dichotomy’, Genomics, Society and Policy 6 (2010), pp. 33–46.
4. J. Bovenberg, ‘Legal Pathways for Cross-border Research: Building a Legal Platform for
Biomedical Academia’, European Journal of Human Genetics 15 (2007), pp. 522–524.
5. Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the
protection of individuals with regard to the processing of personal data and on the free
movement of such data, OJ L 281. Available at: http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri¼CELEX:31995L0046:en:HTML (accessed 8 July 2014).
Moraia et al. 189
project,6 which aims to develop tools to enable statistical analyses of large-scale data
across different studies. The question underlying our analysis is whether the different
requirements for accessing data in each of these jurisdictions may make it difficult for
researchers to conduct studies that use samples and data obtained from a number of bio-
banks. We discovered firstly that there are considerable differences in the way that the
data protection principles are implemented into national law, which reflect the different
legal traditions of the BioSHaRE-EU countries. Secondly, there are three key areas of
considerable differences between the requirements in these countries. These are the def-
inition of ‘personal data’, requirements for pseudonymization and rules on processing of
data for medical research, and they do not appear to have been addressed in the current
version of the proposed EU Data Protection Regulation.
Those differences imply that researchers seeking access to biobanks located in differ-
ent countries may be required to be compliant with different rules. For example, such a
fragmented framework creates bureaucratic impediments for researchers,7 as well as an
increasing sense of uncertainty regarding the legal requirements found in the different
EU member states, discouraging collaboration between researchers and, therefore, inno-
vation. Since there are different types of biobanks, it seems that there is a need for a spe-
cific and unique body of regulations at European or international level, which could
better address the legal challenges raised by biobanking research than the current general
and fragmented system.
Data protection law
Legal framework across BioSHaRE-EU jurisdictions
Biobanks contain samples and associated clinical data, so the law that applies to the use
of data for medical research purposes is highly relevant to biobanking activities. The
laws relating to the processing of personal data in Europe share a common origin in the
Data Protection Directive,8 and therefore member states should implement the same core
principles regarding the processing, storage and uses of data. The Article 29 Data Pro-
tection Working Party9 set up under this Directive has been highly influential in the
interpretation of the Directive’s principles and provisions. The Working Party is com-
posed of representatives from the member states’ Data Protection Authorities, the EU
Commission and the EU Data Protection Supervisor, which is an independent authority.
6. BioSHaRE is a consortium of leading biobanks and international researchers from all
domains of biobanking science. Available at: https://www.bioshare.eu/ (accessed 8 April
2014).
7. F. Colledge, B. Elger and H.C. Howard, ‘A Review of the Barriers to Sharing in Biobanking’,
Biopreservation and Biobanking 11(6) (2013), p. 343.
8. Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the
protection of individuals with regard to the processing of personal data and on the free
movement of such data.
9. Available at: http://ec.europa.eu/justice/data-protection/article-29/index_en.htm (accessed 8
April 2014).
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The margin of appreciation that member states can exercise in the implementation of
Directives is particularly evident in regard to the Data Protection Directive.10 In our case
study of the BioSHaRE-EU jurisdictions, there are differences in the way that the Direc-
tive is implemented, which reflect the jurisprudential traditions of member states and
whether they have specific legislation that applies to patients or medical research. The
common approach is to develop national data protection acts based on the EU Data Pro-
tection Directive. However, this legislation does not always contain all the relevant rules.
Instead, some are found elsewhere in other national legal instruments. Most countries
also have a specific legislation on medical research that must be read along with the data
protection legislation to provide a comprehensive picture of the legal requirements that
apply to medical research.
In Finland, the Personal Data Act (523/1999) implemented the Data Protection Direc-
tive and governs research use of data.11 There are also specific laws that apply to
patients, which give strength to the data protection provisions, such as the Patient Rights
Act (785/1992). As in other jurisdictions, the Personal Data Act is lex generalis. This
means that it provides an overall framework for the use of data, and there are specific
provisions that apply to medical research elsewhere. This is common to all the other
BioSHaRE-EU jurisdictions.
In Germany, rather than detailed procedural legal provisions regulating the use of tis-
sues and data, biomedical research relies on respecting constitutionally enshrined indi-
vidual rights, with strong jurisprudential links to dignity and personality rights.12
Accompanying these national rights, as in all of the BioSHaRE-EU jurisdictions, are the
10. See in general also J.-E. Litton and J. Bovenberg, ‘To Explore Pan-European Solutions for
the Cross-border Data Protection Issues Associated with BBMRI’, BBMRI Joint Deliverable
WP5 (2011); T. Lemmens and L. Austin, ‘The End of Individual Control over Health
Information: Promoting Fair Information Practices and Governance of Biobank Research’,
in J. Kaye and M. Stranger, eds. Principles and Practice in Biobank Governance.
(Farnham: Ashgate, 2009), p. 243.
11. Section 8 states that personal data shall be processed only if the data subject (i) has
unambiguously consented to it, (ii) has given an assignment for the same or (iii)
processing is necessary (inter alia) in order to (a) perform a contract to which the data
subject is a party; (b) take steps at the request of the data subject before entering into a
contract; (c) protect the vital interests of the data subject (in an individual case); (d)
processing is based on the provisions of an Act or it is necessary for compliance with a
task or obligation to which the controller is bound by virtue of an Act or an order issued
on the basis of an Act; (e) there is a relevant connection between the data subject and the
operations of the controller, based on the data subject being a client or member of, or in
the service of, the controller or on a comparable relationship between the two (connection
requirement). In these cases personal data may be disclosed only if (i) such disclosure is a
regular feature of the operations concerned, (ii) the purpose for which the data is
disclosed is not incompatible with the purposes of the processing and (iii) it can be
assumed that the data subject is aware of such disclosure. English translation is available
at: http://www.finlex.fi/fi/laki/kaannokset/1999/en19990523.pdf (accessed 8 April 2014).
12. J. Simon et al, ‘A Legal Framework for Biobanking: The German Experience’, European
Journal of Human Genetics 15 (2007), pp. 528–532.
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standard, harmonized data protection provisions present through the implementation of
the Data Protection Directive (with minor deviations, as shown below) through the Fed-
eral Data Protection Act (DPA) (Bundesdatenschutzgesetz),13 which applies only to the
bodies mentioned in section 1(2).14 For other bodies, the DPAs of the La¨nder (federal
states) are applicable. Additional norms are found in canonical law (for hospitals run
by the churches) and each federal state has a variety of differing data protection and hos-
pital laws that address data protection issues, that is, the applicability of these norms
depends on the legal status of the entity using the data. The fragmentation of the sources
of law in this country is therefore considerably higher when compared to the other
BioSHaRE-EU countries.
In the Netherlands, in addition to the Personal Data Protection Act (PDPA) of 2000
(Wet bescherming persoonsgegevens), which implements the European Commission
(EC) Directive, there are other laws, not specifically addressing biobanks but specifically
addressing the collection and linking of data for (biomedical) research (FEDERA
codes).15 The Dutch Civil Code (Burgerlijk Wetboek) also contains provisions that relate
to the transfer of personal information from medical records for research purposes, with-
out the need for consent, which are similar to the ones implemented in the PDPA. The
two provisions differ slightly and in case of a conflict of terms, the more stringent pro-
visions from Civil Code prevail.
In contrast to the other BioSHaRE-EU jurisdictions, the Norwegian legislative frame-
work puts all research use of personal health data and samples under the same legislative
instrument, known as the Health Research Act 2008 (HRA; Helseforskningsloven).16
13. Federal Data Protection Act (BDSG), in the version promulgated on 14 January 2003
(Federal Law Gazette I, p. 66), last amended by Article 1 of the Act of 14 August 2009
(Federal Law Gazette I, p. 2814), in force from 1 September 2009. An English version of
the Act is available at: http://www.bfdi.bund.de/EN/DataProtectionActs/Artikel/BDSG_
idFv01092009.pdf?__blob¼publicationFile (accessed 8 July 2014).
14. That is (1) public bodies of the Federation; (2) public bodies of the La¨nder insofar as data
protection is not governed by Land legislation and insofar as they (a) execute federal law
or (b) act as bodies of the judicature and are not dealing with administrative matters; (3)
private bodies insofar as they process or use data by means of data processing systems or
collect data for such systems, process or use data in or from non-automated filing systems
or collect data for such systems, except where the collection, processing or use of such
data is effected solely for personal or family activities. Federal Data Protection Act
(BDSG), section 1(2).
15. See the Codes of Conduct for medical research set out by the Dutch Council of the Federation
of Medical Scientific Societies (Federatie Van Medisch Wetenschappelijke Verenigingen).
Available at: http://www.federa.org/gedragscodes-codes-conduct-en (accessed 8 April
2014).
16. The Health Research Act 2008 (Helseforskningsloven) has superseded the Personal Data
Act 2000, as well as Patients’ Rights Act (1999 No. 63) and the Personal Health Data
Filing System Act 2001 (Act of May 2001 No. 24 on Personal Health Data Filing
Systems and the Processing of Personal Health Data), Biobanks Act 2003, Application
of Biotechnology in Human Medicine Health Act 2003.This Act applies only to research
conducted in Norway or conducted under the direction of a person or body responsible
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It applies to all medical and health research, which is defined as ‘the use of scientific
methods to generate new knowledge about health and disease’, and it applies to research
conducted on human beings, human biological material or personal health data, includ-
ing pilot studies and experimental treatments.17 There are also common rules regarding
the use of human biological material and personal health data.
In the UK, there are no biobank-specific laws but rather a combination of general
statutory and regulatory provisions, common law doctrines and guidance docu-
ments.18 Rules governing access to data are contained in the DPA 1998 and in the
Data Protection (Processing of Sensitive Personal Data) Order 2000,19 making it rel-
atively easy to find out where the Directive provisions have been implemented.
Unlike Finland, Norway and the Netherlands where there is specific legislation that
applies to medical research, the UK has no specific statute for patient rights and med-
ical research. The closest that the UK gets in this regard are the Medicines for Human
Use (Clinical Trials) Regulations 2004, which set out good practice in the conduct of
clinical trials.20
The Data Protection Directive is to be replaced with a new regulation,21 which, unlike
Directives, would have direct effect in all EU member states without having to be imple-
mented in national law. The intention is that the new Data Protection Regulation will
result in a single set of rules across Europe. However, although expressly intended to
strengthen the rights of individuals, current drafts of the Regulation could potentially
have a negative impact on health research.22 There has been concern as to whether the
for the research established in Norway. It does not apply to use of personal health data if (i)
the person or body responsible for the research is established in another European
Economic Area (EEA) State; (ii) the person or body responsible for the research is
established in a state outside the EEA and the institution does not use tools in Norway
for purposes other than pure transfer of personal health data. Clinical testing of
medicinal products on human beings is covered by the Medicines Act and appurtenant
regulations. Clinical testing of medical equipment is covered by the Act on Medical
Equipment and appurtenant regulations. In this context, the provisions of the Biobank
Act apply as a supplement, where relevant.
17. See para. 2 of the Health Research Act.
18. L. Curren, P. Boddington, H. Gowans, N. Hawkins, N. Kanellopoulou, J. Kaye J, and K.
Melham, ‘Identifiability, Genomics and U.K. Data Protection Law’, European Journal of
Health Law 17(4) (2010), 329–344; S.M.C. Gibbons, Elsagen UK Law Report, (April
2004), 14.
19. Data Protection Act 1998, 16 July 1998, Available at: http://www.legislation.gov.uk/ukpga/
1998/29/contents and The Data Protection (Processing of Sensitive Personal Data) Order
2000 (accessed 17 February 2000). Available at: http://www.legislation.gov.uk/uksi/2000/
417/introduction/made (accessed 8 April 2014).
20. Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/ 1031)
21. The latest draft is available at: http://www.europarl.europa.eu/sides/getDoc.do?type¼TA&
reference¼P7-TA-2014-0212&language¼EN&ring¼A7-2013-0402 (accessed 8 July 2014).
22. See the ‘Wellcome Trust open letter re: amendments to EU Data Protection Regulation’,
Available at: http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communi
cations/documents/web_document/WTP055585.pdf (accessed 8 April 2014), and the
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proposed regulation will prohibit the use of a broad consent in biobanking and much of
the epidemiological research carried out on registries.23
Key differences
Just as significant variation exists in the way that the BioSHaRE-EU countries have imple-
mented and enforced the provisions of theData ProtectionDirective, there are also differences
in the way that the various elements of the Directive have been interpreted. This makes for
considerable complexity and requires specialist knowledge of local interpretation. There are
three key areas of difference in interpretation, namely, the definition of personal data, the
notionof pseudonymization and the requirements for processingof data for researchpurposes.
Personal data. Biobanks provide access not only to human samples but also to differentmed-
ical information, such as genomic data, population genetic data and molecular data. In this
framework, data sharingmay refer to the transfer of any typeof personal and/or sensitive data
referring to the donor, clinical data as well as data deriving from the analysis of samples.24
The definition of personal and sensitive data, as mentioned in the EU Directive, has
been implemented by member states. It has a broad scope and therefore leaves space to a
broad interpretation. Even if there are some slight differences in how it has been
‘Impact of the draft European Data Protection Regulation and proposed amendments from the
rapporteur of the LIBE committee on scientific research’, available at: http://www.
wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_
document/wtvm054713.pdf (accessed 8 April 2014).
23. Jan Philipp Albrecht; ‘rapporteur’ for the data protection dossier:
DRAFT REPORT on the proposal for a regulation of the European Parliament and of the Council
on the protection of individual with regard to the processing of personal data and on the free move-
ment of such data (General Data Protection Regulation) (COM(2012)0011 – C7-0025/2012 –
2012/0011(COD)).
Available at: http://www.europarl.europa.eu/meetdocs/2009_2014/documents/libe/pr/922/
922387/922387en.pdf (accessed 8 July 2014). On the possible impact of the Draft
Regulation (before the Albrecht amendments), see G. Lauss, A. Bialobrzeski, M.
Korkhaus, K. Snell, J. Starkbaum, A.E. Vermeer, J. Weigel, H. Gottweis, I. Hele´n, J.
Taupitz and P. Dabrock, ‘Beyond genetic privacy. Past, Present and Future of
Bioinformation Control Regimes’, (2013), 45. Available at: http://private-gen.eu/uploads/
media/PRIVATE_Gen_FINAL-REPORT_2013_01.pdf (accessed 2 February 2015). On
the impact of the EU Regulation on biomedical research after Albrecht amendments, see
M.C. Ploem, M.L. Essink-Bot, ‘Proposed EU Data Protection Regulation is a Threat to
Medical Research’, British Medical Journal 364 (2013), f3534; Protecting health and
scientific research in the Data Protection Regulation (2012/0011(COD)): Position of non-
commercial research organisations and academics - July 2014. Available at: http://
www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/
web_document/WTP055584.pdf (accessed 2 February 2014); L. Briceno Moraia and
J. Kaye, ‘Spies, Data and Research’, EMBO Reports, 15(2) (2014), p. 123.
24. F. Colledge, B. Elger and H.C. Howard, ‘A Review of the Barriers to Sharing in Biobanking’,
Biopreservation and Biobanking 11(6) (2013), p. 344.
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implemented by BioSHaRE-EU jurisdictions, they are not likely to have an impact on
practice. Nevertheless, different interpretations of what data could be considered as per-
sonal data, and therefore of what enables identification of the individual, may influence
the assessment of which data, under certain conditions, shall be anonymized or pseudo-
nomized (see subsection (b) below).
Under Article 2(a) of the Data Protection Directive:
‘‘personal data’’ shall mean any information relating to an identified or identifiable natural
person (‘data subject’); an identifiable person is one who can be identified, directly or indir-
ectly, in particular by reference to an identification number or to one or more factors spe-
cific to his physical, physiological, mental, economic, cultural or social identity.
There are two important elements to this definition. Firstly, the data subject must be a
natural person, and secondly, the list of factors that can make an individual identifiable.
The Directive does not provide any other detailed rules with regard to genetic data, but
the latest draft of the EU Data Protection Regulation includes this kind of data, following
European Court of Human Rights case law.25 Prior to this, the Article 29 Working Party
introduced the topic of the protection of genetic data in its Work Programme in 2003 and
highlighted the fact that even though some member states explicitly listed genetic data as
sensitive data, this processing is not always regulated by specific legislation but by com-
plementary rules on patient’s rights.26 It is in this area where there are specific differ-
ences between five of the BioSHaRE-EU countries.
Each of the BioSHaRE-EU jurisdictions adhere to the spirit of the Directive defini-
tion, by stating that personal data are data that relate to an identified or identifiable nat-
ural person. However, there are subtle differences between the BioSHaRE-EU
jurisdictions on even this most basic element of the Directive. For example, under Article
1(a) of the Dutch Data Protection Directive, ‘personal data’ means any information relat-
ing to an identified or identifiable natural person, but under section 3(1) of the German
Data Protection Act personal data means ‘any information concerning the personal or
material circumstances of an identified or identifiable individual (the data subject)’.
‘Material circumstances’ is much broader than the comprehensive list of items that
makes up the Directive’s definition under Article 2(a) and a broader approach may have
been endorsed by the announcement in the Work Programme 2007 that there should be
avoidance of ‘unduly restricting the interpretation of the concept of personal data’.27
25. See Article 9 of the Proposal for a regulation of the European Parliament and of the
Council on the protection of individuals with regard to the processing of personal
data and on the free movement of such data (COM(2012)0011 Available at: http://
www.europarl.europa.eu/sides/getDoc.do?pubRef¼-%2F%2FEP%2F%2FTEXT%2BREP
ORT%2BA7-2013-0402%2B0%2BDOC%2BXML%2BV0%2F%2FEN&language¼EN#
title1. (accessed 8 July 2014).
26. See Article 29 Data Protection Working Party, 12178/03/EN WP 91, Working Document on
Genetic Data, 17 March 2004, 3. Available at: http://ec.europa.eu/justice/policies/privacy/
docs/wpdocs/2004/wp91_en.pdf (accessed 8 April 2014).
27. Opinion 4/2007 on the concept of personal data, WP136 (2007), Available at: http://ec.
europa.eu/justice/policies/privacy/docs/wpdocs/2007/wp136_en.pdf
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Whilst the Directive refers in general to a ‘natural person’, section 1(1) of the UK
DPA 1998 defines personal data as data relating to a ‘living individual’. The living indi-
vidual is someone who can be identified (a) from those data or (b) from those data and
other information which is in the possession of, or is likely to come into the possession
of, the data controller and include any expression of opinion about the individual and any
indication of the intentions of the data controller or any other person in respect of the
individual. As with other BioSHaRE-EU countries, this definition of personal data
recalls the text of Article 2 of the EC Directive but with the peculiarity that the UK DPA
specifies the variety of sources from which the information may be derived28 rather than
the factors to which it may be related (physical, physiological, mental etc.). The inclu-
sion of any data or information likely to come into the possession of the data controller
means that this definition of personal data is broader than in the other BioSHaRE-EU
countries. The UK DPA definition of ‘sensitive personal data’ recalls the categories to
which the Directive refers and contains a list of kinds of information that can be consid-
ered sensitive data, including any data relating to the physical or mental health condition
of the data subject (section 2(e)). This is another difference in legal approach because
even though health data are implicitly considered sensitive personal data in all the
BioSHaRE-EU jurisdictions, only in the UK and in Norway is there an explicit reference
to physical or mental health data in law.
It is in Finland and in Norway where there is greatest deviation from the specifications
of the Data Protection Directive. Whilst the Finnish DPA basically follows the require-
ments of the Directive, there is a difference in the interpretation of personal data. Under
the Finnish DPA, personal data means ‘any information on a private individual and any
information on his/her personal characteristics or personal circumstances, where these
are identifiable as concerning him/her or the members of his/her family or household’
(section 3).29 This is a significant difference because it includes information relating
to ‘members of his/her family or household’ and is unlike any of the other jurisdictions.
Arguably, however, such an approach is in line with the Article 29 Working Group’s
inclusion of genetic information as ‘personal information’ and also with the intent of the
proposed EU Data Protection Regulation to support a broad definition of personal data.
28. Under Article 1(1) of the UK Data Protection Act:
unless the context otherwise requires ‘‘data’’ means information which – (a) is being processed by
means of equipment operating automatically in response to instructions given for that purpose, (b)
is recorded with the intention that it should be processed by means of such equipment, (c) is
recorded as part of a relevant filing system or with the intention that it should form part of a rel-
evant filing system, [F1 . . . ] (d) does not fall within paragraph (a), (b) or (c) but forms part of an
accessible record as defined by section 68; [F2] or (e) is recorded information held by a public
authority and does not fall within any of paragraphs (a) to (d); [ . . . ].
29. And in particular, ‘if they relate to or are intended to relate to [ . . . ] the state of health, illness
or handicap of a person or the treatment or other comparable measures directed at the person’
(section 11, (4)); (2) processing of personal data means ‘the collection, recording,
organisation, use, transfer, disclosure, storage, manipulation, combination, protection,
deletion and erasure of personal data, as well as other measures directed at personal data’.
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In Norway, under para. 4(d) of the Norwegian HRA, personal health data are
defined as ‘confidential information pursuant to Section 21 of the Health Personnel
Act and other information and assessments concerning health issues or that are sig-
nificant for health issues that can be linked to an individual person’. This defini-
tion is broad enough to include genetic data as suggested by the Article 29
Working Party and in the proposed draft of the Data Protection Regulation under
Article 4(2) and (10) (definitions).30 Article 4(10) further specifies that:
. . . ‘‘genetic data’’ means all personal data relating to the genetic characteristics of an indi-
vidual which have been inherited or acquired as they result from an analysis of a biological
sample from the individual in question, in particular by chromosomal, deoxyribonucleic
acid (DNA) or ribonucleic acid (RNA) analysis or analysis of any other element enabling
equivalent information to be obtained.
Pseudonymization. Anonymization and consent are used to protect privacy interests,
but both may restrict data sharing. In some cases, such as in the field of biobank-
ing research, it is recognized that it is not possible to reach a complete anonymi-
zation31 and therefore the threshold is limited to the pseudonymization
requirement, and consent is not required if certain conditions, including coding,
are fulfilled.
Another area of national variation in the interpretation of the EU Directive is
the definition of pseudonymization. Under the Directive, data protection principles
shall not apply to data rendered anonymous in such a way that the data subject is
no longer identifiable. To determine whether a person is identifiable ‘account
should be taken of all the means likely reasonably to be used either by the control-
ler or by any other person to identify the said person’ (Recital 26).32 The Directive
does not provide further rules regarding anonymized, coded or pseudonymized
30. ‘Personal data’ means any information relating to an identified or identifiable natural person
(‘data subject’); an identifiable person is one who can be identified, directly or indirectly, in
particular by reference to an identifier such as a name, an identification number, location
data, unique identifier or to one or more factors specific to the physical, physiological,
genetic, mental, economic, cultural or social or gender identity of that person, Available
at: http://www.janalbrecht.eu/fileadmin/material/Dokumente/DPR-Regulation-inofficial-
consolidated-LIBE.pdf (accessed 8 April 2014).
31. J. Kaye, N. Kanellopoulou, N. Hawkins, H. Gowans, L. Curren and K. Melham, ‘Can I
Access my Personal Genome? The Current Legal Position in the UK’, Medical Law
Review 22(1) (2014), p. 64; N. Homer and others, ‘Resolving Individuals Contributing
Trace Amounts of DNA to Highly Complex Mixtures using High-density SNP
Genotyping Microarrays’, PLoS Genet 4(8) (2008), p. e1000167. Available at: http://
www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1000167 (accessed
24 October 2014).
32. ‘principles of protection must apply to any information concerning an identified or
identifiable person: to determine whether a person is identifiable, account should be taken
of all the means likely reasonably to be used either by the controller or by any other
person to identify the said person’ Recital (26).
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data.33 However, the Article 29 Working Party (Work Programme 2007) has con-
sidered pseudonymization and defined it as:
. . . the process of disguising identities. The aim of such a process is to be able to collect
additional data relating to the same individual without having to know his identity. This
is particularly relevant in the context of research and statistics.
Pseudonymization means that the individual is indirectly identifiable so data rules
will apply but in the opinion of the Article 29 Working Party, ‘the application of these
rules will justifiably be more flexible than if information on directly identifiable individ-
uals were processed’.34 Pseudonymization is often used in research as it may be neces-
sary to link the data with the data subject, for example, in a longitudinal cohort where
different sources of data relating to an individual need to be linked over time.
In each of the BioSHaRE-EU jurisdictions, there are considerable differences in how
these provisions are interpreted and what it means to pseudonymize data. This has sig-
nificant implications for the transfer of data across borders as being able to use pseudo-
nymized data is crucial for research conducted by large international consortia that
operate across jurisdictional borders. The law provides limited guidance on what is
required of researchers when they pseudonymize data.
The Finnish DPA does not contain specific rules regarding anonymized, coded or
pseudonymized data. However, as the concept of personal data includes identifiable
information relating to the family or household of an individual, this implies a higher
level of safeguards will be necessary to reduce the risk of re-identification. The interpre-
tation by the Data Ombudsman of Recital 26 of the Directive has been that any data that
could be linked to a person is regarded as personal data, even if, for example, the iden-
tifier is administered by a third party. This sets a very high standard for researchers, even
those taking reasonable precautions and leaving a low likelihood that data could be
linked to the individual will be dealing with personal data.
In contrast to the Directive and the Finnish legislation that do not contain specific pro-
visions on anonymization, pseudonymization or coded data, the German DPA defines
the concept of ‘rendering anonymous’. This is ‘the alteration of personal data so that
33. It only recognizes that (within the meaning of Article 27) ‘codes of conduct may be a useful
instrument for providing guidance as to the ways in which data may be rendered anonymous
and retained in a form in which identification of the data subject is no longer possible’, see
Recital (26) of the Data Protection Directive.
34. ‘Indeed, using a pseudonym means that it is possible to backtrack to the individual, so that
the individual’s identity can be discovered, but then only under predefined circumstances. In
that case, although data protection rules apply, the risks at stake for the individuals with
regard to the processing of such indirectly identifiable information will most often be
low, so that the application of these rules will justifiably be more flexible than if
information on directly identifiable individuals were processed’ (Article 29 Working
Party, Opinion 4/2007 on the concept of personal data, 20 June 2007, WP 136 2007).
Available at: http://ec.europa.eu/justice/policies/privacy/docs/wpdocs/2007/wp136_en.
pdf#page¼15&zoom¼auto,0,844 (accessed 2 February 2012).
198 Medical Law International 14(4)
information concerning personal or material circumstances cannot be attributed to an
identified or identifiable natural person or that such attribution would require a dispro-
portionate amount of time, expense and effort’.35However, this is another example of how
general data protection rulesmay not be fitting for the protection of sensitive personal data
in the context of biomedical research, for example, DNA is a unique identifier and there-
fore it is impossible to completely anonymize a sample.36 It has been demonstrated that it
is possible to identify individuals when genome-wide methodologies are used.37
Personal data collected or recorded for the purpose of scientific research may be pro-
cessed or used only for these purposes and shall be rendered anonymous as soon as the
research purpose allows. Until then, the features enabling the attribution of information
concerning personal or material circumstances to an identified or identifiable person
shall be kept separately. They may be combined with the information only to the extent
required by the research purpose. Bodies conducting scientific research may publish per-
sonal data only if (a) the data subject has consented and (b) this is essential to present
research findings concerning events of contemporary history. Personal data should not
be transferred if the data subject has a legitimate interest in ruling out the possibility
of transfer, especially if the bodies fail to ensure an adequate level of data protection.38
As in Finland, the UK DPA does not expressly refer to anonymized data, but it refers
to the concept of identification or likelihood of identification through linkage of data in a
similar way to the Directive. The Information Commissioner’s Office Code of Practice
on anonymization explains that ‘this means that, although it may not be possible to deter-
mine with absolute certainty that no individual will ever be identified as a result of the
disclosure of anonymised data, this does not mean that personal data has been dis-
closed’.39 Recent case law has also addressed this issue in relation to statistical medical
data.40 In general, data no longer fall under the data protection principles, if through
statistical disclosure control methods, the data are anonymized so that the chance of
re-identification is very remote and the data can no longer be classed as personal.41
35. See section 3(6) of the German Data Protection Act.
36. J. Kaye, C. Heeney, N. Hawkins and J. de Vries, P. Boddington, ‘Data Sharing in Genomics –
Re-shaping Scientific Practice’, Nature Reviews, Genetics 10 (2009), 334.
37. N. Homer, et al. ‘Resolving Individuals Contributing Trace Amounts of DNA to Highly
Complex Mixtures Using High-density SNP Genotyping Microarrays’, PLoS Genetetics 4
(2008), p. e1000167; J. Couzin, ‘Genetic Privacy. Whole-genome Data not Anonymous,
Challenging Assumptions’, Science 321 (2008), p. 1278.
38. See section 4b (1). Nevertheless, this rule should not apply if transfer is necessary for a public
body of the Federation to carry out its duties for compelling reasons of defence or to fulfil
supranational or intergovernmental obligations in the field of crisis management or
conflict prevention or for humanitarian measures.
39. Information Commissioner’s Office, ‘Anonymisation: managing data protection risk code of
practice’, para. 16.
40. For example, R (on the application of the Department of Health) v. Information
Commissioner [2011] EWHC 1430 (Admin).
41. Information Commissioner’s Office (2012). Available at: http://www.ico.org.uk/for_
organisations/data_protection/topic_guides/*/media/documents/library/Data_Protection/
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As in Finland and in the UK, anonymization is not covered by Dutch DPA, but it is
covered by the Civil Code. In situations where consent ‘cannot reasonably be
requested’, researchers may obtain access to medical information or have it trans-
ferred to them for research provided that suitable guarantees are taken as regards the
patient’s privacy.42 Anonymization is required so that ‘data are supplied in such a
form that they cannot be traced back to individual as to ensure that traceability to a
natural person is reasonably prevented’.42 The transfer of such information research
must be in the public interest, the research cannot be carried out without the medical
information from the patient’s record and the patient must not have explicitly objected
to such use of their medical record.43 This appears to be in line with the safeguards
generally present in health research aimed at reducing the risk of re-identification, but
it does not take into account both its feasibility with regard to genetic data and the
need for the researcher in certain cases to trace back the information to the individual
patient. In particular, such a system may limit secondary uses of the data where spe-
cific contextual factors are needed.44 However, such considerations have been taken
into account in the federa codes,45 which allow tracing back in certain instances, and
by Article 10 of the Dutch DPA, which states that even if personal data shall not be
kept in a form allowing the identification of the data subject for any longer than nec-
essary for the purposes of the processing, it recognizes that they may be kept for lon-
ger where this is for historical, statistical or scientific purposes and where the
responsible party has made the necessary arrangements to ensure that the data con-
cerned are used solely for these specific purposes. This rule implements the principle
contained in the Directive to allow further scientific data use where member states
have developed ‘suitable safeguards’ (see Recital 29) but specifies it with regard to
Practical_application/anonymisation_code.ashx) (accessed 8 April 2014). See also R.
Massey, ’Anonymisation: Managing Data Protection Risk – the New UK Code’,
Computer and Telecommunications Law Review 19 (2013), p. 86.
42. Article 7:458 of the Dutch Civil Code:
Without prejudice to [existing obligations of secrecy] information about the patient or access to
[medical files] may, if requested, be supplied to another person for the purpose of statistics or sci-
entific research in the field of public health without the patient’s consent, if a) consent cannot rea-
sonably be requested and guarantees are provided that the patient’s privacy will not be inordinately
infringed by the conduct of the research; b) consent cannot reasonably be requested given the
nature and purpose of the research and the care provider has ensured that the data are supplied
in such a form as to ensure that they cannot be traced back to individual natural persons.
43. See Article 7:458.
44. S. Lindsay and J. Goldring, ‘Anonymizing Data for Secondary Use’, Encyclopedia of Case
Study Research 2010, Available at: http://srmo.sagepub.com/view/encyc-of-case-study-
research/n10.xml (accessed 2 february 2014); K.E. Emam, Methods for De-identification
of Electronic Health Records for Genomic Research’, Genome Medicine 3 (2011), 25.
45. Codes of Conduct for medical research set out by the Dutch Council of the Federation of
Medical Scientific Societies (Federatie Van Medisch Wetenschappelijke Verenigingen).
Available at: http://www.federa.org/gedragscodes-codes-conduct-en (accessed 8 April 2014).
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data that may actually be traced back to the individual (see Article 10 para. 1).46 As
per a ruling of the Dutch Data Protection Agency, pseudonymization under certain
conditions is deemed to render personal data anonymous and so has the effect of mak-
ing the DPA no longer applicable to data thus pseudonymized. This ruling is heavily
relied upon for purposes of health research.47
Unlike Finland, the Netherlands and the UK, which do not contain specific provisions
regarding anonymization in their DPA, para. 20 of the Norwegian HRA states that
consent is not required for research on anonymous human biological material and
anonymous data, but it is required to collect material and data for subsequent anon-
ymization.48 As in the Dutch law, para. 38 further specifies that data must not be
stored for longer periods than is necessary to complete the project, but the Norwe-
gian Act also foresees the possibility of a different ruling by the regional ethic com-
mittee for medical and health research. The Committee:
may rule that documents necessary for auditing the project must be kept for five years after
the final report on the research project has been sent to the Committee, or for longer under
certain conditions, and that if the data are not going to be kept thereafter in accordance with
the Archives Act or other legislation, they must be anonymised or deleted.49
This rule, which refers in general to research using personal data, allows researchers
the possibility of being able to have access to those data also for longer than necessary to
complete the project, depending on a Research Ethics Committee (REC) decision. On
the other hand, complete anonymization (when feasible) or deletion of the data may
interfere with sharing data with researchers based in different jurisdictions, in particular
for all secondary uses.
The latest draft of the proposed EU Data Protection Regulation contains a definition
of ‘pseudonymous data’ under Article 4(2a), ‘personal data that cannot be attributed to a
specific data subject without the use of additional information, as long as such additional
information is kept separately and subject to technical and organisational measures to
ensure non-attribution’. It is not clear whether pseudonymized data are intended to be
included in the scope of the draft regulation, a concern raised by a coalition of European
stakeholders who suggested that ‘the Albrecht amendments would create a system in
which the use of pseudonymised data is subject to most of the same regulatory
46. Article 7:458 of the Dutch Civil Code ‘ . . . the care provider has ensured that the data are
supplied in sucha formas to ensure that theycannot be tracedback to individual natural persons’.
47. Available at: http://www.medlaw.nl/wp-content/uploads/commentsdutchrshgdprv22.pdf at 2
(accessed 8 July 2014).
48. Cf. para. 20 of the Health Research Act under section 21. Research on human biological
material from deceased persons. Research on biological material taken from deceased
persons is correspondingly subject to the provisions in Act of 9 February 1973 no. 6
relating to transplantation, hospital autopsies and the donation of bodies and so on and
regulations issued pursuant to this Act.
49. Para. 38, ‘‘Prohibition against storing unnecessary personal health data’’, Dutch Health
Research Act, 2008-06-20 n. 44.
Moraia et al. 201
requirements as identifiable data’.50 This could potentially increase the burden on rele-
vant sectors of biomedical research, for example, large-scale population-based studies
and cohorts involving biobanks and patient data.51
As pseudonymized data implies that the individual is still ‘identifiable’, it may be dif-
ficult to draw the line between what falls under the Data Protection Directive and what
does not. The Data Protection Directive does not contain a definition of those terms, and
our analysis shows that there are some differences across EU member states.
The lack of a unique definition has important implications for both donors and research-
ers since anonymized data do not fall under the scope of the data protection regulation and
therefore may be freely accessible for research purposes. However, anonymization makes
re-contact impossible. Such situation may raise issues for cross-border research, where the
legal framework may vary from state to state, as well as in all the cases where re-contacting
participants is fundamental to the progress of the research itself.52,53
Processing of personal data. Under Article 2(b) of the Directive 95/46/EC ‘processing of
personal data’ means:
‘any operation or set of operations which is performed upon personal data, whether or not by
automatic means, such as collection, recording, organization, storage, adaptation or altera-
tion, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise
making available, alignment or combination, blocking, erasure or destruction’.
50. Available at: http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communi
cations/documents/web_document/wtvm054713.pdf (accessed 8 July 2014). Under
Amendment 23 of the so-called Albrecht amendments:
[ . . . ] This Regulation should not apply to anonymous data, meaning any data that cannot be
related, directly or indirectly, alone or in combination with associated data, to a natural person
or where establishing such a relation would require a disproportionate amount of time, expense,
and effort, taking into account the state of the art in technology at the time of the processing and
the possibilities for development during the period for which the data will be processed. (accessed
8 April 2014). Available at: http://www.janalbrecht.eu/fileadmin/material/Dokumente/DPR-Reg-
ulation-inofficial-consolidated-LIBE.pdf (accessed 2 Februaty 2015).
51. See ‘Impact of the draft European Data Protection Regulation and proposed Amendments
from the rapporteur of the LIBE committee on scientific research’, March 2013, available
at: http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/doc
uments/web_document/wtvm054713.pdf (accessed 8 April 2014).
52. M. Barbareschi, S. Fasanella, C. Cantaloni and S. Giuliani, ‘Scientific and Managerial
Premises and Unresolved Issues in Tumor Biobanking Activities’, in G. Pascuzzi, U. Izzo
and M. Macilotti, eds. Comparative issues in the governance of research biobanks.
(Berlin Heidelberg:Springer, 2013), pp. 301–309.; G. Laurie, P. Mallia, David A. Frenkel,
A. Krajewska and H. Moniz, ‘Managing Access to Biobanks: How Can We Reconcile
Individual Privacy and Public Interest in Genetic Research?’, Medical Law International
10(4) (2010), pp. 315–337.
53. J. Kaye, ‘From Single Biobanks to International Networks: Developing E-governance’,
Human Genetics 130 (2011), p. 377.
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The Directive first sets out general conditions under which the processing of personal
data is lawful (Article 7), leaving member states the possibility to determine these con-
ditions more precisely. Then it prohibits the processing of special categories of data, like
data concerning health, with the exception of certain cases. Data sharing is a form of data
processing, as defined by the EU Directive 95/46/EC on data protection. Therefore, it is
particularly important that data sharing in the context of biobanking research is based on
uniform and harmonized requirements across member states.54 Since funding bodies are
increasingly requiring data sharing as a consideration of funding applications, this may
be difficult to achieve if data processing rules as implemented by member states are
slightly different one from each other.
Under Article 8(2), the processing of special categories of data, like data concerning
health, will only be permitted if:
(a) the data subject has given his explicit consent to the processing of those data, except
where the laws of the Member State provide that the prohibition may not be lifted by the
data subject’s giving his consent; or ( . . . ) (c) processing is necessary to protect the vital
interests of the data subject or of another person where the data subject is physically or leg-
ally incapable of giving his consent.
The processing will also be permitted if it:
is required for the purposes of preventive medicine, medical diagnosis, the provision of care
or treatment or the management of health-care services, and where those data are processed
by a health professional subject under national law or rules established by national compe-
tent bodies to the obligation of professional secrecy or by another person also subject to an
equivalent obligation of secrecy. (Article 8(3))
Subject to the provision of suitable safeguards, member states may, for reasons of
substantial public interest, lay down exemptions in addition to those laid down in para.
2 either by national law or by decision of the supervisory authority (Article 8(4)). Sec-
tion VIII of the Data Protection Directive also sets forth rules regarding the confiden-
tiality and security of processing. Provisions regarding processing vary across the
BioSHaRE-EU jurisdictions in slightly different ways.
The Finnish DPA implements the Directive rules without major differences.55 The
general principle is that the processing of sensitive data is prohibited, but some deroga-
tions are possible.56 It follows the Directive but sets more detailed safeguards, which are
far more specific also compared to the other BioSHaRE-EU countries.
54. B.M. Knoppers, J.R. Harris, A.M. Tasse, I. Budin-Liøsne, J. Kaye, M. Descheˆnes and M.
Zawati, ‘Towards a Data Sharing Code of Conduct for International Genomic Research’,
Genome Medicine 3 (2011), p. 46. Available at: http://genomemedicine.com/content/3/7/46
55. See chapter 3 of the Finnish Data Protection Act, section 12, para. (1)–(12).
56. Under para. 2, ‘Sensitive data shall be erased from the data file immediately when there no
longer is a reason for its processing, as provided in paragraph (1). The reason and the need for
processing shall be re-evaluated at five-year intervals at the longest, unless otherwise
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This could potentially complicate the creation of a common data sharing policy across
biobanks or cohorts located in different jurisdictions since it must be compliant with the
more specific Finnish requirements.
Section 14 (Chapter 4) of the FinnishDPA allows the processing of personal data for spe-
cial purposes, with regard to historical or scientific research if the following specific condi-
tions are fulfilled: (i) The research cannot be carried out without data identifying the person
and the consent of the data subject cannot be obtained owing to the quantity of the data, their
age or another comparable reason; (ii) the use of the personal data file is based on an appro-
priate researchplan and a personor a group of persons responsible for the researchhavebeen
designated; (iii) the personal data file is used and data are disclosed only for the purposes of
historical or scientific research and the procedure followed does not disclose data pertaining
to a given individual to outsiders; and (iv) after the personal data are no longer required for
the research or for the verification of the results achieved, the personal data file is destroyed
or transferred to an archive, or the data in it are altered so that the data subjects can no longer
be identified. However, the Finnish DPA further clarifies that these provisions do not apply
if this procedure is manifestly unnecessary for the protection of the privacy of the data sub-
ject owing to the age or quality of the data in the personal data file.57
Complementary and derogating provisions are also found in other specific Finnish
laws. For example, the Act on the Status and Rights of Patients (the Patient Rights Act,
785/1992) regulates the use of patient records for research, that is, access to such records
for research purposes is subject to a license granted locally by a local health care unit.
Where several records are used from different regions, the National Institute for Health
and Welfare may give permission to access this data.58 There is a similar legislative sit-
uation in the other BioSHaRE-EU jurisdictions with the exception of Norway, where the
HRA supersedes the DPA as well the other complementary regulations.
With regard to the processing of data by public bodies, the requirements in Germany are
the sameas the ones set out in theDataProtectionDirective, butwith an important difference
regarding the form required for expressing consent. The processing shall be lawfulwhen the
knowledge of such data is necessary for the controller to perform its tasks and where (i) the
data subject has given his/her consent in accordancewith section 4a(3), required for the pur-
poses of preventive medicine, medical diagnosis, the provision of care or treatment or the
provided in an Act or stated in a permission of the Data Protection Board referred to in’. See
also Finnish National Ethics Committee (2005), ‘Human Stem Cells, Cloning and Research’;
Finnish National Ethics Committee, ‘Opinion on EU research funding on stem cells’, 28
February 2006; Finnish National Ethics Committee, ‘Statement on Human Dignity and
Rights of the Foetus’, 13 April 2010.
57. See section 14, para. 2 of the Finnish Data Protection Act.
58. What is provided in the Act on the Openness of Government Activities, Patient Rights Act
section 13, para. 4: Personal Data Registers for Health Care (556/1989) and in the Personal
Data Act shall apply to the supplying of information contained in patient documents for
scientific research and compilation of statistics. Patient Rights Act imposes secrecy on
patient records and they shall not be disclosed to a third party without patient’s consent.
However, see section 28 of the Official Act. See also Act 795/2010 and the Act on
National Personal Data Registers for Health Care (556/1989).
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management of health-care services; (ii) these data are processed by health professionals or
other persons subject to the obligation of professional secrecy; (iii) the processing is neces-
sary for the purposes of scientific research, where the scientific interest in carrying out the
research project significantly outweighs the data subject’s interest in ruling out the possibil-
ity of collection and the purpose of the research cannot be achieved in any other way or
would require a disproportionate effort. A unique feature of the German law compared to
the other BioSHaRE-EU data protection laws, and which goes beyond the requirements
of the Directive, is that consent for processing data shall be given in writing, unless special
circumstances warrant any other form.59 Consent shall be based on the data subject’s free
decision, who shall be informed of the purpose of collection, processing or use, as necessary
in the individual case or on request, of the consequences of withholding consent.
The following special circumstances that may warrant forms other than writing occur:
(a) in the field of scientific research, where the defined purpose of research would be
seriously affected if consent were obtained in writing. Irrespective, it is necessary to
record in writing for (i) the purpose of collection, processing or use, (ii) the consequences
of withholding consent and (iii) the reasons the defined purpose of research would be
seriously affected60; and (b) any other form other than written may be justified where
special categories of personal data (section 3(9)) are collected, processed or used, that
is, information on racial or ethnic origin, political opinions, religious or philosophical
beliefs, trade union membership, health or sex life.61 Despite these exceptions, requiring
the written form as a general rule reflects the more restrictive approach to data protection
rules found in Germany as compared to the other BioSHaRE-EU jurisdictions. Where
consent is absent, the processing and use of personal data shall be lawful only if it is per-
mitted or ordered by the Federal DPA or other law.62
Processing of personal data under the Dutch DPA reflects the rules contained in the EC
Directive, as in the other BioSHaRE-EU jurisdictions. The general principle is that consent
is required,63 and it should be obtained respecting the relevant conditions. Under Article 16
of theDutchAct, it is prohibited to process personal data concerning a person’s health,64 but
this prohibition does not apply where the processing is (i) carried out with the express con-
sent of the data subject, (ii) carried outwithout their express consent, but for the benefit of an
important public interest, (iii) carried out where appropriate guarantees have been put in
place to protect the individual’s privacy and (iv) provided for by law, or the Data Protection
Commission has granted an exemption.When granting an exemption, the Commission can
impose rules and restrictions. It is possible to process personal data without expressing con-
sent for the purpose of scientific research or statistics, if (i) the research serves a public inter-
est, (ii) the processing is necessary for the research or statistics concerned, (iii) it appears
to be impossible or would involve a disproportionate effort to ask for express consent and
59. If consent is to be given together with other written declarations, it shall be made
distinguishable in its appearance. See section 4(1) of the German Data Protection Act.
60. See section 4a(2) of the German Data Protection Act.
61. See section 3(9) of the German Data Protection Act.
62. See section 4 of the German Data Protection Act.
63. See Article 23 of the Dutch Personal Data Protection Act.
64. See Article 21 of the Dutch Personal Data Protection Act.
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(iv) sufficient guarantees are provided to ensure that the processingdoes not adversely affect
the individual privacy of the data subject to a disproportionate extent.65 In all these cases, the
datamay only beprocessed bypersons subject to anobligation of confidentialitybyvirtue of
office, profession or legal provision or under an agreement.
There are some provisions in the UK DPA that relate specifically to health/medical
research and bypass the need for a data subject’s consent. However, the general principle
is that to have access to data it is necessary to obtain consent from the data subject and also
to comply with the relevant conditions set out in the DPA, that is, (i) data are not processed
to support measures or decisions with respect to particular individuals and (ii) they are not
processed in such a way that substantial damage or substantial distress is, or is likely to be,
caused to any data subject.66 The processing must comply with one of the conditions set
out in Schedule 2 of the DPA. Under the Act, any data related to physical or mental health
or condition is considered ‘sensitive personal data’. For this kind of data, it is not nec-
essary to obtain a data subject’s consent (exemption from section 7),67 if personal data
are processed only for research purposes (which includes statistical or historical pur-
poses) and (i) they are processed in compliance with the relevant conditions,68 (ii) the
results of the research or any resulting statistics are not made available in a form that
identifies data subjects or any of them.69 Any processing necessary for medical pur-
poses, including medical research,70 shall be undertaken by (a) a health professional
65. See Article 23.2 of the Dutch P Personal Data Protection Act. Moreover, under Article 44:
1. Where processing is carried out by institutions or services for the purposes of scientific research
or statistics, and the necessary arrangements have been made to ensure that the personal data can
only be used for statistical or scientific purposes, the responsible party shall not be required to pro-
vide the information referred to in Article 34 and may refuse to comply with the requests referred
to in Article 35.
66. Section 33(3) of the UK Data Protection Act. Personal data that are processed only for
research purposes in compliance with the relevant conditions may, notwithstanding the
fifth data protection principle, be kept indefinitely.
67. Para. 7 of UK Data Protection Act, Right of access to personal data.
68. Schedule 2 and 3 UK Data Protection Act and para. 9 of the Data Protection Order 2000. The
circumstances under which sensitive personal data may be processed are set out in the Data
Protection (Processing of Sensitive Personal Data) Order 2000. In particular, see para. 9(b).
69. Section 33 of the UK Data Protection Act:
(5) For the purposes of subsections (2) to (4) personal data are not to be treated as processed oth-
erwise than for research purposes merely because the data are disclosed – (a) to any person, for
research purposes only, (b)to the data subject or a person acting on his behalf, (c)at the request,
or with the consent, of the data subject or a person acting on his behalf, or (d) in circumstances
in which the person making the disclosure has reasonable grounds for believing that the disclosure
falls within paragraph (a), (b) or (c).
70. Section 4(3) UK Data Protection Act, ‘(2) In this paragraph ‘‘medical purposes’’ includes the
purposes of preventative medicine, medical diagnosis, medical research, the provision of
care and treatment and the management of healthcare services’.
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or (b) a person who in the circumstances owes a duty of confidentiality, which is equiv-
alent to that which would arise if that person were a health professional.71
To meet the conditions for research, sensitive personal data may be processed where
the processing is in the substantial public interest and does not support measures or deci-
sions with respect to any particular data subject otherwise than with their explicit con-
sent. Processing shall not cause, nor shall be likely to cause, substantial damage or
substantial distress to the data subject or any other person. Personal data shall not be
transferred to a country or territory outside the EU unless that country or territory ensures
an adequate level of protection for the rights and freedoms of data subjects in relation to
the processing of personal data.72 If data are anonymized, it can be transferred across
borders without explicit consent.
As in the UK, there are also specific rules tailored to processing of health data in
Norwegian law. Besides the main rule on consent expressed by para. 13 of the Act,
chapter 7 specifically considers research using personal health data. The general prin-
ciple is that consent must be obtained from participants in medical and health research,
unless the law provides otherwise. It must be (i) informed, (ii) voluntary, (iii) express
and documented and (iv) based on specific information about a concrete research proj-
ect, unless there is a case for granting broad consent. Research participants may con-
sent to human biological material and personal health data being used for ‘specific,
broadly defined research purposes’. This means that a broad consent model is
expressly allowed under this new regime (see para 14). Processing of personal health
data in medical and health research must comply with the conditions set forth in para
32 of the HRA:
i. it must have expressly indicated objectives,
ii. the health data must be relevant and necessary to achieve the objective of the
research project,
iii. the degree of personal identification in the health data must not be greater than is
necessary to serve the intended purposes and
iv. it may not be used for purposes that are incompatible with the original objective
without the consent of the research participant, unless otherwise prescribed by law.
Researchers must obtain a new consent where the research project has changed sub-
stantially, if these changes are deemed to have consequences for the participant’s con-
sent. Otherwise the regional committee for medical and health research ethics may
approve new or changed use of previously collected human biological material or
71. Schedule 3, para. 8 of the UK Data Protection Act.
72. Information Commissioner’s Office, 8th Data Protection Principle, available at: http://ico.
org.uk/for_organisations/data_protection/the_guide/the_principles (accessed 8 July 2014).
Such a rule does not apply if there is i) DS consent, ii) contract between DS and DC, iii) contract
between data controller and third parties (related to DS/DC relationship), iv) Public interest, v)
Legal proceedings, vi) Vital interest of DS, vii) Data is on a public record, viii) Uses EC –
approved model contract, ix) Transfer is authorized by the EC. See schedule 4(1)–(9).
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personal health data without new consent being obtained if (i) it is difficult to obtain it,
(ii) the research in question is of significant interest to society and (iii) the participants’
welfare and integrity are ensured.
In the latest version of the proposed EU Data Protection Regulation, draft Article 9
sets out a general prohibition of processing special categories of personal data and excep-
tions to this general rule, building on Article 8 of the Directive by adding genetic data.
Under the current system, consent is one of the alternatives among equally valid bases
for lawful processing (see Article 8.2[a]–[e] of the Directive), but under the proposed
Regulation, processing of health data would be possible only with the consent of the data
subject, under the conditions and safeguards referred to in Articles 81 and 83.73 Members
states would have to set an exemption of ‘high public interest’ for research without con-
sent (Article 81(2)(a)). The new approach of the proposed EU Data Protection Regula-
tion has raised a number of concerns, particularly, regarding its potential negative impact
on biomedical and biobanking research. In fact, it leaves member states the possibility to
adopt exceptions for research purposes, without harmonizing the area of scientific
research where sensitive data are being used.
Under the proposed Regulation, processing of health data and therefore sharing data
across biobanks will not only require the relevant consent from the data subject but also
that certain conditions are fulfilled, including, as the proposed Article 83 requires, that
‘data enabling the attribution of information to an identified or identifiable data subject is
[sic] kept separately’ from other information ‘under the highest technical standards’ and
ensuring ‘all necessary measures are taken to prevent unwarranted re-identification’.
The amendment means that the exemption could only apply to the use of pseudony-
mized (or coded) data, even if research serves a high public interest. Moreover, the
wording is not clear and leaves open a number of different interpretations of anon-
ymized or pseudonymized data, and such legal uncertainty may hinder data sharing
across different biobanks.74
Conclusions
This article identifies and compares the key legal requirements regarding research
use of data in Finland, Germany, the Netherlands, Norway and the UK. In all the
BioSHaRE-EU jurisdictions, in addition to the legislation implementing the EU Data
Protection Directive, there are provisions for data protection in other regulations or
sources of law. For example, in patient’s rights legislation (Finland), hospital laws
(Germany), civil codes (Germany and Netherlands), specific HRAs (Norway) or case
law (UK). This fragmentation of the sources of law undermines the certainty of the
rules necessary to guarantee the flow of the information contained in samples between
biobanks and to allow researchers to share them without undue burdens. The proposed
73. Article 9.2 (h) and (i) of the proposed European Union draft Regulation.
74. M. Taylor and B. Thompson, ‘Update on the European Data Protection Regulation’,
Available at: http://www.p3g.org/sites/default/files/site/default/files/Taylor%20Thompson
%20-%20Data%20Protection%20Regulation%20Update%2025%20February%202014%20
V3.pdf (accessed 2 February 2015).
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draft of the EU Regulation on data protection will ensure a single set of rules on data
protection across Europe, explicitly incorporating genetic information, but the latest
amendments contain several changes that overall could have a negative impact on
medical research.
The main grey areas of the 1995 Directive concern the concept of personal data, anon-
ymization and data processing. The definition of personal data adopted in the
BioSHaRE-EU jurisdictions leaves space for broad interpretation to also include genetic
information as sensitive health data. In Finland, the definition of personal data of an indi-
vidual expressly includes ‘members of his/her family or household’. Arguably, this is in
line with the views of the Article 29 Working Group and latest proposals for EU data
protection reform. Anonymization and pseudonymization are not expressly regulated
by the current Directive, which recognizes the possibility of member states adopting
Codes of Practices on the issue. Even though the latest draft of the proposed EU Data
Protection Regulation contains a definition of pseudonymization, it still leaves space for
different interpretations of its scope.
With regard to data processing, the BioSHaRE-EU jurisdictions have implemen-
ted the Directive rules without major differences. The general principle is that the
processing of sensitive data is prohibited unless express consent is provided or when
it is for the purposes of historical, scientific or statistical research. A unique feature
of the German law compared to the other BioSHaRE-EU countries, and which
exceeds the requirements of Data Protection Directive, is that consent for processing
data shall be given in writing.
As far as access to data is concerned, the general principle and the main relevant
exceptions are the same in all BioSHaRE-EU jurisdictions; again, consent of the
data subject is essential, but this requirement can be waived if access is requested
for research purposes and if specific conditions are satisfied. However, these condi-
tions vary from one country to another. The proposed EU Data Protection Regula-
tion would require consent for processing health data for research purposes, leaving
it to member states to introduce exceptions. If member states decide to introduce a
research exemption, it could again lead to different legal requirements across the
EU. This would affect international research consortia that need to share data and,
to an extent, diminish the benefits of a single EU Regulation on data protection for
biomedical research.
Our analysis has shown that although data protection rules across BioSHaRE-EU jur-
isdictions are substantially uniform and share the same European origin, there are still
some grey areas relating to research that have not been clarified or specified at the
national level. This leaves room for different interpretations by national courts. The sit-
uation is further complicated by the variety of regulations and sources of law through
which EU data protection rules have been implemented in each member state, raising
further problems linked to the hierarchy of the law. Importantly, even if a single EU Data
Protection Regulation were enacted and directly applicable in all member states, as the
current proposals stand, it would not provide enough clarification to remove the existing
grey areas for data-based research. Unfortunately, the EU data protection law reform
process seems to have taken insufficient account of the importance of data sharing for
biomedical research and, ultimately, population health.
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The peculiarities of biomedical research call for a specific regulation at European
level, which could apply both for samples and data. In fact, there is a straight link-
age between samples and data, that is, researchers require access to a sample in
order to get the information contained in it, and the usefulness of biological samples
for research is greatly reduced when associated data are not shared with the samples.
Nevertheless, they are considered as two different legal entities as different sources
of law regulate access to data and samples. Following the Norwegian example, hav-
ing a unique regulation, applying both to samples and data, and specific, focusing on
biomedical research, would clear the path towards simplification of the sources of
law, guaranteeing a better harmonization across member states and the desired shar-
ing of data across different jurisdictions.
The BioSHaRE-EU project tries to overcome the legal restraints by encouraging the
development of cutting-edge technologies that enhance collaborations among investi-
gators and enable the development of tools for data harmonization, database integra-
tion and federated data analysis.75 In particular, it has proposed a new approach,
named DataSHIELD,76 a federated infrastructure allowing researchers to jointly ana-
lyse harmonized data whilst retaining individual-level data within their respective host
institutions.77 Such a system enables to share data for research purposes without the
need to physically pool them together, therefore avoiding to incur in the traditional
legal constraints.
The BioSHaRE-EU Healthy Obese Project aims to gain insights into the conse-
quences of (healthy) obesity using data on risk factors and phenotypes across several
large-scale cohort studies.78 This project has combined 10 different cohorts in seven
countries, using data transformed into a harmonized format, that is, it has used a com-
puting infrastructure to enable the effective pooling of data and research into critical
sub-components of the phenotypes associated with common complex diseases.79
75. D. Doiron et al., ‘Data Harmonization and Federated Analysis of Population-based Studies:
The BioSHaRE Project’, Emerging Themes in Epidemiology 10 (2013), p. 12. Available at:
http://www.webcitation.org/query.php?url¼http://www.bioshare.eu&refdoi¼10.1186/1472-
6823-14-9 (accessed 2 February 2015).
76. (Data aggregation through anonymous summary statistics from harmonized individual level
databases), M. Wolfson et al., ‘DataSHIELD: Resolving a Conflict in Contemporary
Bioscience – Performing a Pooled Analysis of Individual-level Data Without Sharing the
Data’, International Journal of Epidemiology 39(5) (2010), pp. 1372–1382.
77. D. Doiron et al., ‘Data Harmonization’.
78. J.V.van Vlier-Ostaptchouk et al., ‘The Prevalence of Metabolic Syndrome and Metabolically
Healthy Obesity in Europe: A Collaborative Analysis of Ten Large Cohort Studies’, BMC
Endocrine Disorders 14 (2014), p. 9. Available at: http://www.biomedcentral.com/1472-
6823/14/9 (accessed 2 February 2015).
79. Vlier-Ostaptchouk et al., ‘Metabolic Syndrome’. The data harmonization and database
federation methodology and infrastructure developed and piloted under BioSHaRE’s HOP
is founded on the DataSchema and Harmonization Platform for Epidemiological Research
harmonization approach and on information technology tools developed by OBiBa (Open
Source Software for BioBanks), see D. Doiron et al., ‘Data Harmonization’.
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BioSHaRE-EU has also supported the development of the so-called ‘omics connect
toolbox’, which includes a set of software to be locally used by researchers for omics
data validation, management, viewing and sharing.80
It has been created also a unified system to integrate and compare observation data
across experimental projects, disease databases and clinical biobanks; the system com-
prises models, formats documentation and software that are all available for free and
open source at http://www.observ-om.org.81
At the same time, BioSHaRE-EU cohorts do not have a common access policy, that is,
researchers still need to contact each cohort individually to get access authorization. To
overcome some of the issues raised by not having such ‘common data access policy’, an
internal process has been developed, allowing tracking which cohorts under the
BioSHaRE-EU project have provided access authorization for research.82
The BioSHaRE-EU project shows that cutting-edge technologies could enable effec-
tive sharing of data overcoming legal constraints and at the same time raises the question
on whether different kind of governance systems are needed to support the current lack
of a uniform regulatory framework.83
80. A. J. Brookes et al., ‘Omics Connect Toolbox: A Management, Validation and Visualisation
Toolkit for Complex Omics Data, European Society of Human Genetics conference 2013’,
poster, Available at: https://www.bioshare.eu/content/omics-connect-toolbox-management-
validation-and-visualisation-toolkit-complex-omics-data (accessed 2 February 2015).
81. T. Adamusiak et al., ‘Observ-OM and Observ-TAB: Universal Syntax Solutions for the
Integration, Search, and Exchange of Phenotype and Genotype Information’, Human
Mutation 33(5) (2012), pp. 867–873.
82. Process and Data Access Schema developed by A. M. Tasse et. al. within the BioSHaRE-EU
project. Data Access Procedure:
The Data Access procedure developed in BioSHaRE ensures that the research is feasible, does not
conflict with other BioSHaRE research projects, and central governance of access to the data (Fig-
ure). 1.Investigators submit a research protocol to the Access Coordination Committee and the har-
monization team, describing the research question, required variables and planned statistical
analyses. The protocol is reviewed to assess potential overlap with ongoing research in the Core Proj-
ect, to confirm the feasibility to harmonize the variables, and to perform analyses using
DataSHIELD.
2. Investigators request approval from their respective research ethics or data access
committees to obtain the data. Approvals are registered and overseen centrally. 3. The
Access Coordination Committee informs the harmonization team about the approved
protocols and oversees investigator access to the data. 4. The harmonization team informs
the central IT office and develops the processing algorithms. 5. The central IT office
guides and instructs the local IT staff in installing the processing algorithms, providing
access to registered investigators, updating software, etc. 6. The central IT office grants
DataSHIELD access to registered investigators to use DataSHIELD on variables defined
in their research protocol and only for the biobanks that approved the protocol.’’ The
approved protocols are published at the BioSHaRE website.
83. J. Kaye, ‘Single Biobanks’, pp. 377-382; J. Kaye, ‘Do We Need a Uniform Regulatory
System for Biobanks Across Europe?’, European Journal of Human Genetics 14(2)
(2006), pp. 245-248.
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